Failure can occur at any point in the process, including after significant funds have been invested.As of December 31, 2022, Abbott's consolidated indebtedness was approximately $16.8 billion.10 Table of ContentsAdditionally, further borrowing could cause a deterioration of Abbott's credit ratings.Abbott’ s profitability is affected by movement of the U. S. dollar against other currencies.Abbott’ s operations and performance depend on its ability to manage its large and complex global supply chain.Legal and Regulatory RisksAbbott is subject to numerous governmental regulations and it is costly to comply with these regulations and to develop compliant products and processes.Any material litigation regarding Abbott’ s patents and trademarks is described in the section captioned“ Legal Proceedings.”In the United States and other countries, Abbott’ s businesses have experienced downward pressure on certain product pricing.Abbott’ s products face intense competition from competitive products.Sales outside of the United States in 2022 made up approximately 58 percent of Abbott’ s net sales.Sales outside of the United States in 2022 made up approximately 58 percent of Abbott’ s net sales.Sales in emerging markets, which represent approximately 35 percent of total company sales, increased 5.6 percent in 2022 and 19.6 percent in 2021, excluding the impact of foreign exchange.Over the last three years, Abbott’ s operating margin as a percentage of sales increased from 15.5 percent in 2020 to 19.6 percent in 2021 and then decreased to 19.2 percent in 2022.Excluding the impact of foreign exchange, Medical Devices operating earnings increased 9.3 percent.In Abbott’ s Diagnostics segment, sales increased 10.4 percent in 2022 and 42.7 percent in 2021, excluding the impact of foreign exchange.In 2022, operating earnings for the Diagnostics segment increased 6.6 percent.Operating margins for the worldwide nutritional products business decreased from 22.9 percent in 2020 to 9.5 percent in 2022.Abbott declared dividends of $1.92 per share in 2022 and $1.82 per share in 2021, an increase of approximately 5.5 percent.In December 2022, Abbott increased the company’ s quarterly dividend by 8.5 percent to $0.51 per share from $0.47 per share, effective with the dividend paid in February 2023.In December 2021, Abbott increased the company’ s quarterly dividend by 4.4 percent to $0.47 per share from $0.45 per share, effective with the dividend paid in February 2022.Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’ s total net sales increased 5.1 percent.In 2021, excluding the impact of COVID-19 testing-related sales, Abbott’ s total net sales increased 15.2 percent.Excluding the impact of foreign exchange, total Nutritional Products sales decreased 6.2 percent in 2022 compared to a 7.7 percent increase in 2021.In 2021, U. S. Pediatric Nutritional sales increased 10.3 percent compared to 2020, reflecting growth in Pedialyte, Similac, and PediaSure. International Pediatric Nutritional sales, excluding the effect of foreign exchange, decreased 3.9 percent in 2022 and 3.2 percent in 2021.In 2021, Rapid Diagnostics sales increased 10.4 percent, excluding COVID-19 testing-related sales, and 9.2 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.In Molecular Diagnostics, sales decreased 27.4 percent in 2022 and 2.9 percent in 2021, excluding the effect of foreign exchange.Excluding the effect of foreign exchange, total Medical Devices sales grew 8.1 percent in 2022 and 19.4 percent in 2021.FreeStyle Libre sales totaled $4.3 billion in 2022, which reflected a 22.4 percent increase, excluding the effect of foreign exchange, over 2021.FreeStyle Libre sales totaled $3.7 billion in 2021, which reflected a 36.8 percent increase, excluding the effect of foreign exchange, over 2020 when sales totaled $2.6 billion.Operating EarningsGross profit margins were 51.5 percent of net sales in 2022, 52.2 percent of net sales in 2021, and 50.5 percent in 2020.Taxes on EarningsThe income tax rates on earnings from continuing operations were 16.5 percent in 2022, 13.9 percent in 2021, and 10.0 percent in 2020.